Oncology

New technology provides information on the benefit of adding atezolizumab to chemotherapy as a neoadjuvant treatment for patients with early high-risk and locally advanced triple-negative breast cancer.

Experts reviewed the efficacy and safety of the recommended treatment regimens and discussed which treatment strategy they would recommend for their patients.

However, active disease alone for hospitalized patients was not associated with greater odds of dying from COVID-19, nor was receiving ongoing cancer treatment.

Uterine cancers that developed in patients with breast cancer treated with tamoxifen had fewer phosphoinositol-3-kinase (PI3K) pathway mutations and may have been driven by tamoxifen-induced PI3K pathway activation.

Data from a couple of new molecules could be encouraging for the treatment of acute myeloid leukemia and diffuse large B-cell lymphoma

Since its initial approval in 2016 for urothelial carcinoma, atezolizumab has received FDA approval for an additional 5 types of carcinomas.

In addition to data showing the durable efficacy of acalabrutinib, other data presented at ASH 2021 demonstrate that the new tablet formulation of the drug supports ease of use for patients

The study demonstrates a need for novel tolerable and efficacious therapeutic agents to address the burden of illness in patients with multiple myeloma, according to the investigators.

Pharmacists have an important role in the optimization of AML therapies.

Data support daratumumab as part of a standard of care regimen in the frontline setting for patients with newly diagnosed multiple myeloma.

The investigators said this increase in risk is particularly pronounced in those with more advanced disease.

Acalabrutinib could offer a high level of confidence for patients looking at a long course of disease.

Overall, approximately 41% of those receiving Axi-cel and 16% of those receiving standard of care survived for 2 years without needing additional cancer treatment or experiencing cancer progression.

Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses ongoing trials assessing efficacy and safety of asciminib in the treatment of chronic myeloid leukemia.

The standard-of-care for patients with LBCL consists of chemotherapy and additional high intensity chemotherapy followed by stem cell transplantation.

CAR T-cell therapy shows durable long-term survival in patients with refractory LBCL, company’s Kite subsidiary says.

Advancements in genomic and mutational analysis show that up to 60% of adenocarcinomas and up to 50% to 80% of squamous cell carcinomas (SCC) have a known oncogenic driver mutation.

According to the investigators, in vitro functional studies demonstrate potent antitumor activity of ATA2271 following repeat antigen stimulation.

The combination of tislelizumab and chemotherapy demonstrated a statistically significant improvement in progression-free survival.

Belzutifan is indicated for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors.

Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses how the ASCEMBL study data may impact treatment strategies and approaches for patients with chronic myeloid leukemia.

Following the success of ibrutinib, second-generation BTK inhibitors have shown even better outcomes with fewer toxicities.

The body of research around acalabrutinib is becoming quite advanced, allowing clinicians to feel confident when treating patients.

Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses how asciminib has impacted the treatment landscape for chronic myeloid leukemia.

New data are being presented at ASH 2021 regarding the durable efficacy of acalabrutinib in chronic lymphocytic leukemia.

The multicenter phase 3 study randomized patients with R/R CLL 1:1 to receive acalabrutinib 100 mg orally twice daily or investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab until disease progression or unacceptable toxicity.

Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses new longer-term efficacy and safety data from the pivotal phase 3 ASCEMBL study.

The combination therapy of ibrutinib and venetoclax was superior to chlorambucil and obinutuzumab in terms of undetectable minimal residual disease responses in elderly or unfit patients with previously untreated chronic lymphocytic leukemia.